NTP-LEFLUNOMIDE TABLET
Država: Kanada
Jezik: angleščina
Source: Health Canada
Lastnosti izdelka
(SPC)
11-10-2013
Nekateri dokumenti za ta izdelek trenutno niso na voljo, pošljete lahko zahtevo v našo stranko in obvestili vas bomo takoj, ko jih bomo lahko pridobili.
Pošlji zahtevo.
Pošlji zahtevo.
Aktivna sestavina:
LEFLUNOMIDE
Dostopno od:
TEVA CANADA LIMITED
Koda artikla:
L04AK01
INN (mednarodno ime):
LEFLUNOMIDE
Odmerek:
10MG
Farmacevtska oblika:
TABLET
Sestava:
LEFLUNOMIDE 10MG
Pot uporabe:
ORAL
Enote v paketu:
30
Tip zastaranja:
Prescription
Terapevtsko območje:
DISEASE-MODIFYING ANTIRHEUMATIC AGENTS
Povzetek izdelek:
Active ingredient group (AIG) number: 0140182001; AHFS:
Status dovoljenje:
CANCELLED PRE MARKET
Datum dovoljenje:
2015-08-06
Lastnosti izdelka
PRODUCT MONOGRAPH
Pr
NTP-LEFLUNOMIDE
(Leflunomide)
10 mg and 20 mg Tablets
Antirheumatic Agent
Teva Canada Ltd.
30 Novopharm Court
Toronto, Ontario
M1B 2K9
Submission Control No.: 167474
Date of Preparation:
October 11, 2013
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.................................................................... 3
INDICATIONS AND CLINICAL USE
..........................................................................
3
CONTRAINDICATIONS
...............................................................................................
3
WARNINGS AND PRECAUTIONS
..............................................................................
5
ADVERSE REACTIONS
..............................................................................................
13
DRUG INTERACTIONS
..............................................................................................
17
DOSAGE AND ADMINISTRATION
..........................................................................
21
OVERDOSAGE
............................................................................................................
22
ACTION AND CLINICAL PHARMACOLOGY
........................................................ 22
STORAGE AND STABILITY
......................................................................................
25
DOSAGE FORMS, COMPOSITION AND PACKAGING
......................................... 25
PART II: SCIENTIFIC INFORMATION
...............................................................................
27
PHARMACEUTICAL INFORMATION
......................................................................
27
CLINICAL TRIALS
......................................................................................................
28
DETAILED PHARMACOLOGY
.................................................................................
35
TOXICOLOGY
.......................................................................
Preberite celoten dokument
